ComplicationsBy Mayo Clinic Staff
Parkinson's disease is often accompanied by these additional problems, which may be treatable:
- Thinking difficulties. You may experience cognitive problems (dementia) and thinking difficulties, which usually occur in the later stages of Parkinson's disease. Such cognitive problems aren't very responsive to medications.
Depression and emotional changes. People with Parkinson's disease may experience depression. Receiving treatment for depression can make it easier to handle the other challenges of Parkinson's disease.
You may also experience other emotional changes, such as fear, anxiety or loss of motivation. Doctors may give you medications to treat these symptoms.
- Swallowing problems. You may develop difficulties with swallowing as your condition progresses. Saliva may accumulate in your mouth due to slowed swallowing, leading to drooling.
Sleep problems and sleep disorders. People with Parkinson's disease often have sleep problems, including waking up frequently throughout the night, waking up early or falling asleep during the day.
People may also experience rapid eye movement sleep behavior disorder, which involves acting out your dreams. Medications may help your sleep problems.
- Bladder problems. Parkinson's disease may cause bladder problems, including being unable to control urine or having difficulty urinating.
- Constipation. Many people with Parkinson's disease develop constipation, mainly due to a slower digestive tract.
You may also experience:
July 07, 2015
- Blood pressure changes. You may feel dizzy or lightheaded when you stand due to a sudden drop in blood pressure (orthostatic hypotension).
- Smell dysfunction. You may experience problems with your sense of smell. You may have difficulty identifying certain odors or the difference between odors.
- Fatigue. Many people with Parkinson's disease lose energy and experience fatigue, and the cause isn't always known.
- Pain. Many people with Parkinson's disease experience pain, either in specific areas of their bodies or throughout their bodies.
- Sexual dysfunction. Some people with Parkinson's disease notice a decrease in sexual desire or performance.
- Longo DL, et al. Parkinson's disease and other movement disorders. In: Harrison's Principles of Internal Medicine. 18th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://accessmedicine.com. Accessed April 6, 2015.
- Parkinson's disease: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. Accessed April 6. 2015.
- Ferri FF. Parkinson's disease. In: Ferri's Clinical Advisor 2015: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed April 6, 2015.
- Chou KL. Diagnosis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Tarsy D. Pharmacologic treatment of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Adler CH, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014;82:858.
- Bousquet M, et al. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Research Reviews. 2011;10:453.
- Parkinson's disease: Fitness counts. National Parkinson Foundation. http://www.parkinson.org/Search-Pages/Search.aspx?pKeywords=fitness. Accessed April 9, 2015.
- Parkinson's disease. Natural Medicines Comprehensive Database. http://www.naturaldatabase.com. Accessed April 6, 2015.
- Tarsy D. Nonpharmacologic management of Parkinson disease. http://www.uptodate.com/home/. Accessed April 6, 2015.
- Complementary therapies and Parkinson's. Parkinson's Disease Society of the United Kingdom. http://www.parkinsons.org.uk/content/complementary-therapies-and-parkinsons-booklet. Accessed April 9, 2015.
- Jankovic J. Etiology and pathogenesis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6, 2015.
- Riggs EA. Decision Support System. Mayo Clinic, Rochester, Minn. April 16, 2015.
- Abbvie announces U.S. approval of duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson's disease. http://abbvie.mediaroom.com/2015-01-12-AbbVie-Announces-U-S-FDA-Approval-of-DUOPA-carbidopa-and-levodopa-Enteral-Suspension-for-the-Treatment-of-Motor-Fluctuations-in-Patients-with-Advanced-Parkinsons-Disease. Accessed April 20, 2015.
- Bower JH (expert opinion). Mayo Clinic, Rochester, Minn. April 20, 2015.